Literature DB >> 8495757

Luteinizing hormone: its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase.

Z Shoham1, H S Jacobs, V Insler.   

Abstract

OBJECTIVE: To review studies that have examined the role of LH, its mechanism of action, and its detrimental effects when hypersecreted during the follicular phase.
DESIGN: Important published studies related to this topic were identified through a computerized bibliographic search. PATIENTS, PARTICIPANTS: Review of the need for LH during the follicular phase is based on animal models and women with hypogonadotropic hypogonadism. The association of hypersecretion of LH during the follicular phase with low rates of fertilization and high rates of pregnancy loss is based on clinical studies conducted in patients treated by IVF and ET and by induction of ovulation. The possible mechanism by which the effects occur is based on in vitro studies.
RESULTS: The results of the studies cited in this review are consistent with the two-cell two-gonadotropin hypothesis implying that synergistic action of both FSH and LH is required for appropriate steroidogenesis. It also seems that, whatever the underlying mechanism, a raised serum LH concentration during the follicular phase confers a substantial risk of infertility and early pregnancy loss.
CONCLUSION: By reviewing the literature it appears that LH exhibits an important role in the development of the growing follicle and maturation of the oocyte. It also seems that hypersecretion of LH during the follicular phase implies adverse effects on the fertility process. To further test this hypothesis, we now need systemic assessment of the methods of therapy used for treating patients with polycystic ovary syndrome, in relation to LH secretion and outcome of pregnancy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495757     DOI: 10.1016/s0015-0282(16)55968-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  28 in total

1.  Regulation of lutropin circulatory half-life by the mannose/N-acetylgalactosamine-4-SO4 receptor is critical for implantation in vivo.

Authors:  Yiling Mi; Steven D Shapiro; Jacques U Baenziger
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Leutinizing hormone/choriogonadotropin receptor and follicle stimulating hormone receptor gene variants in polycystic ovary syndrome.

Authors:  Wassim Y Almawi; Bayan Hubail; Dana Z Arekat; Suhaila M Al-Farsi; Shadha K Al-Kindi; Mona R Arekat; Naeema Mahmood; Samira Madan
Journal:  J Assist Reprod Genet       Date:  2015-02-04       Impact factor: 3.412

Review 3.  The role of luteinizing hormone activity in controlled ovarian stimulation.

Authors:  N Angelopoulos; A Goula; G Tolis
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

4.  Relative bioactivity of endogenous luteinizing hormone during superovulation therapy for in vitro fertilization in normal-cycling women.

Authors:  M I Abuzeid; J K Hodges; C R Harlow; M G Hull
Journal:  J Assist Reprod Genet       Date:  1996-09       Impact factor: 3.412

5.  Reduced in vitro fertilization of human oocytes correlates with raised circulating FSH levels during ovarian stimulation in normogonadotropic women downregulated with GnRH-analogues.

Authors:  C Y Andersen; L G Westergaard; A G Byskov; K Erb
Journal:  J Assist Reprod Genet       Date:  1997-11       Impact factor: 3.412

6.  Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors.

Authors:  K A Risma; C M Clay; T M Nett; T Wagner; J Yun; J H Nilson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

7.  The safety and effectiveness of stepwise and low-dose administration of follicle stimulating hormone in WHO group II anovulatory infertile women: evidence from a large multicenter study in Spain.

Authors:  J Balasch; R Tur; P Alvarez; J M Bajo; E Bosch; I Bruna; P Caballero; J Calaf; I Cano; E Carrillo; J A Duque; G Folguera; A de la Fuente; C Jiménez; G Laguens; E López; A Lozano; A Matarranz; C Moreno; J Nava; M Sanchis; E Temprano; G Ventura; J A Peinado
Journal:  J Assist Reprod Genet       Date:  1996-08       Impact factor: 3.412

8.  LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.

Authors:  F P Hohmann; J S E Laven; A G M G J Mulders; J J L Oberyé; B M J L Mannaerts; F H de Jong; B C J M Fauser
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

Review 9.  Contemporary pharmacological manipulation in assisted reproduction.

Authors:  Judith A F Huirne; Cornelis B Lambalk; Andre C D van Loenen; Roel Schats; Peter G A Hompes; Bart C J M Fauser; Nick S Macklon
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Comparison of the ultrashort gonadotropin-releasing hormone agonist-antagonist protocol with microdose flare -up protocol in poor responders: a preliminary study.

Authors:  Bülent Berker; Candan İltemir Duvan; Cemil Kaya; Ruşen Aytaç; Hakan Satıroğlu
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.